Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera

• Hauptverfasser: Aaron T Gerds (Verfasst von), Claudia Castro (Verfasst von), Frank Snopek (Verfasst von), Megan M Flynn (Verfasst von), Alexandra G Ellis (Verfasst von), Meredith Mannin (Verfasst von), Ray Urbanski (Verfasst von)
• Format: Buch
• Veröffentlicht: Becaris Publishing Limited, 2023-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi R ) was approved in the US to treat adults with PV. The purpose of thi...